The NLRP3 inflammasome: Physiopathology and therapeutic application

Thomas Gicquel; Sacha Robert; Tatiana Victoni; Vincent Lagente

doi:10.1016/j.lpm.2016.01.006

The NLRP3 inflammasome: Physiopathology and therapeutic application

Thomas Gicquel, Sacha Robert, Tatiana Victoni, Vincent Lagente

Biomedical Engineering

Research output: Contribution to journal › Short survey › peer-review

7 Scopus citations

Abstract

The innate immune system constitutes the first line of host defense against pathogens. “Nonself”, such as exogenous particles or pathogens, triggers an inflammatory response. Inflammasomes are molecular platforms activated upon cellular infection or stress that trigger the maturation of proinflammatory cytokines such as IL-1β. Activation of the NLRP3 inflammasome pathway, the most extensively studied, appears to be the corner stone of many inflammatory diseases, including Crohn's disease, rheumatoid arthritis and gout. Cryopyrine-associated periodic syndromes (CAPS) are NLRP3 inflammasome-associated diseases. Canakinumab (Ilaris^®) is the only drug approved for CAPS treatment in France. Targeted therapy against NLRP3 inflammasome and IL-1β might be the new anti-inflammatory drugs.

Original language	English (US)
Pages (from-to)	438-446
Number of pages	9
Journal	Presse Medicale
Volume	45
Issue number	4
DOIs	https://doi.org/10.1016/j.lpm.2016.01.006
State	Published - Apr 1 2016

Bibliographical note

Publisher Copyright:
© 2016 Elsevier Masson SAS

Access

10.1016/j.lpm.2016.01.006

OpenUrl availability

Full text

Cite this

@article{bab8f9f8be39460ba51678f58a3f8475,

title = "The NLRP3 inflammasome: Physiopathology and therapeutic application",

abstract = "The innate immune system constitutes the first line of host defense against pathogens. “Nonself”, such as exogenous particles or pathogens, triggers an inflammatory response. Inflammasomes are molecular platforms activated upon cellular infection or stress that trigger the maturation of proinflammatory cytokines such as IL-1β. Activation of the NLRP3 inflammasome pathway, the most extensively studied, appears to be the corner stone of many inflammatory diseases, including Crohn's disease, rheumatoid arthritis and gout. Cryopyrine-associated periodic syndromes (CAPS) are NLRP3 inflammasome-associated diseases. Canakinumab (Ilaris{\textregistered}) is the only drug approved for CAPS treatment in France. Targeted therapy against NLRP3 inflammasome and IL-1β might be the new anti-inflammatory drugs.",

author = "Thomas Gicquel and Sacha Robert and Tatiana Victoni and Vincent Lagente",

note = "Publisher Copyright: {\textcopyright} 2016 Elsevier Masson SAS",

year = "2016",

month = apr,

day = "1",

doi = "10.1016/j.lpm.2016.01.006",

language = "English (US)",

volume = "45",

pages = "438--446",

journal = "Presse Medicale",

issn = "0755-4982",

publisher = "Elsevier Masson",

number = "4",

}

TY - JOUR

T1 - The NLRP3 inflammasome

T2 - Physiopathology and therapeutic application

AU - Gicquel, Thomas

AU - Robert, Sacha

AU - Victoni, Tatiana

AU - Lagente, Vincent

PY - 2016/4/1

Y1 - 2016/4/1

N2 - The innate immune system constitutes the first line of host defense against pathogens. “Nonself”, such as exogenous particles or pathogens, triggers an inflammatory response. Inflammasomes are molecular platforms activated upon cellular infection or stress that trigger the maturation of proinflammatory cytokines such as IL-1β. Activation of the NLRP3 inflammasome pathway, the most extensively studied, appears to be the corner stone of many inflammatory diseases, including Crohn's disease, rheumatoid arthritis and gout. Cryopyrine-associated periodic syndromes (CAPS) are NLRP3 inflammasome-associated diseases. Canakinumab (Ilaris®) is the only drug approved for CAPS treatment in France. Targeted therapy against NLRP3 inflammasome and IL-1β might be the new anti-inflammatory drugs.

AB - The innate immune system constitutes the first line of host defense against pathogens. “Nonself”, such as exogenous particles or pathogens, triggers an inflammatory response. Inflammasomes are molecular platforms activated upon cellular infection or stress that trigger the maturation of proinflammatory cytokines such as IL-1β. Activation of the NLRP3 inflammasome pathway, the most extensively studied, appears to be the corner stone of many inflammatory diseases, including Crohn's disease, rheumatoid arthritis and gout. Cryopyrine-associated periodic syndromes (CAPS) are NLRP3 inflammasome-associated diseases. Canakinumab (Ilaris®) is the only drug approved for CAPS treatment in France. Targeted therapy against NLRP3 inflammasome and IL-1β might be the new anti-inflammatory drugs.

UR - http://www.scopus.com/inward/record.url?scp=84957700124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957700124&partnerID=8YFLogxK

U2 - 10.1016/j.lpm.2016.01.006

DO - 10.1016/j.lpm.2016.01.006

M3 - Short survey

C2 - 26880081

AN - SCOPUS:84957700124

SN - 0755-4982

VL - 45

SP - 438

EP - 446

JO - Presse Medicale

JF - Presse Medicale

IS - 4

ER -

The NLRP3 inflammasome: Physiopathology and therapeutic application

Abstract

Bibliographical note

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this